TOBIRA THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 19
- Market Cap
- -
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Phase 2
Completed
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT01338883
- Locations
- 🇺🇸
Oasis Clinic, Los Angeles, California, United States
🇺🇸Anthony Mills, Los Angeles, California, United States
🇺🇸Providence Clinical Research, Burbank, California, United States
A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients
Phase 1
Completed
- Conditions
- HIV-1 Infection
- Interventions
- Drug: TBR-652 Matching PlaceboDrug: TBR-652 50 mgDrug: TBR-652 75 mgDrug: TBR-652 100 mgDrug: TBR-652 150 mg
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01092104
© Copyright 2025. All Rights Reserved by MedPath